InforMing the PAthway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations.
Aged
Biomarkers
/ blood
Bronchodilator Agents
/ therapeutic use
Disease Progression
Double-Blind Method
Drug Combinations
Female
Fibrinogen
/ metabolism
Humans
Lung
/ drug effects
Male
Middle Aged
Predictive Value of Tests
Pulmonary Disease, Chronic Obstructive
/ blood
Severity of Illness Index
Time Factors
Treatment Outcome
Up-Regulation
COPD
COPD exacerbations
Fibrinogen
Pharmacotherapy
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
28 Apr 2021
28 Apr 2021
Historique:
received:
15
12
2020
accepted:
05
04
2021
entrez:
29
4
2021
pubmed:
30
4
2021
medline:
24
11
2021
Statut:
epublish
Résumé
Fibrinogen is the first qualified prognostic/predictive biomarker for exacerbations in patients with chronic obstructive pulmonary disease (COPD). The IMPACT trial investigated fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus FF/VI and UMEC/VI in patients with symptomatic COPD at risk of exacerbations. This analysis used IMPACT trial data to examine the relationship between fibrinogen levels and exacerbation outcomes in patients with COPD. 8094 patients with a fibrinogen assessment at Week 16 were included, baseline fibrinogen data were not measured. Post hoc analyses were performed by fibrinogen quartiles and by 3.5 g/L threshold. Endpoints included on-treatment exacerbations and adverse events of special interest (AESIs). Rates of moderate, moderate/severe, and severe exacerbations were higher in the highest versus lowest fibrinogen quartile (0.75, 0.92 and 0.15 vs 0.67, 0.79 and 0.10, respectively). The rate ratios (95% confidence interval [CI]) for exacerbations in patients with fibrinogen levels ≥ 3.5 g/L versus those with fibrinogen levels < 3.5 g/L were 1.03 (0.95, 1.11) for moderate exacerbations, 1.08 (1.00, 1.15) for moderate/severe exacerbations, and 1.30 (1.10, 1.54) for severe exacerbations. There was an increased risk of moderate/severe exacerbation (hazard ratio [95% CI]: highest vs lowest quartile 1.16 [1.04, 1.228]; ≥ 3.5 g/L vs < 3.5 g/L: 1.09 [1.00, 1.16]) and severe exacerbation (1.35 [1.09, 1.69]; 1.27 [1.08, 1.47], respectively) with increasing fibrinogen level. Cardiovascular AESIs were highest in patients in the highest fibrinogen quartile. Rate and risk of exacerbations was higher in patients with higher fibrinogen levels. This supports the validity of fibrinogen as a predictive biomarker for COPD exacerbations, and highlights the potential use of fibrinogen as an enrichment strategy in trials examining exacerbation outcomes. NCT02164513.
Sections du résumé
BACKGROUND
BACKGROUND
Fibrinogen is the first qualified prognostic/predictive biomarker for exacerbations in patients with chronic obstructive pulmonary disease (COPD). The IMPACT trial investigated fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus FF/VI and UMEC/VI in patients with symptomatic COPD at risk of exacerbations. This analysis used IMPACT trial data to examine the relationship between fibrinogen levels and exacerbation outcomes in patients with COPD.
METHODS
METHODS
8094 patients with a fibrinogen assessment at Week 16 were included, baseline fibrinogen data were not measured. Post hoc analyses were performed by fibrinogen quartiles and by 3.5 g/L threshold. Endpoints included on-treatment exacerbations and adverse events of special interest (AESIs).
RESULTS
RESULTS
Rates of moderate, moderate/severe, and severe exacerbations were higher in the highest versus lowest fibrinogen quartile (0.75, 0.92 and 0.15 vs 0.67, 0.79 and 0.10, respectively). The rate ratios (95% confidence interval [CI]) for exacerbations in patients with fibrinogen levels ≥ 3.5 g/L versus those with fibrinogen levels < 3.5 g/L were 1.03 (0.95, 1.11) for moderate exacerbations, 1.08 (1.00, 1.15) for moderate/severe exacerbations, and 1.30 (1.10, 1.54) for severe exacerbations. There was an increased risk of moderate/severe exacerbation (hazard ratio [95% CI]: highest vs lowest quartile 1.16 [1.04, 1.228]; ≥ 3.5 g/L vs < 3.5 g/L: 1.09 [1.00, 1.16]) and severe exacerbation (1.35 [1.09, 1.69]; 1.27 [1.08, 1.47], respectively) with increasing fibrinogen level. Cardiovascular AESIs were highest in patients in the highest fibrinogen quartile.
CONCLUSIONS
CONCLUSIONS
Rate and risk of exacerbations was higher in patients with higher fibrinogen levels. This supports the validity of fibrinogen as a predictive biomarker for COPD exacerbations, and highlights the potential use of fibrinogen as an enrichment strategy in trials examining exacerbation outcomes.
TRIAL REGISTRATION
BACKGROUND
NCT02164513.
Identifiants
pubmed: 33910578
doi: 10.1186/s12931-021-01706-y
pii: 10.1186/s12931-021-01706-y
pmc: PMC8080358
doi:
Substances chimiques
Biomarkers
0
Bronchodilator Agents
0
Drug Combinations
0
Fibrinogen
9001-32-5
Banques de données
ClinicalTrials.gov
['NCT02164513']
Types de publication
Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
130Subventions
Organisme : GlaxoSmithKline
ID : Study number: CTT116855
Références
Respir Res. 2019 Apr 1;20(1):63
pubmed: 30935391
N Engl J Med. 2011 Sep 29;365(13):1184-92
pubmed: 21991892
Am J Respir Crit Care Med. 2017 Apr 1;195(7):881-888
pubmed: 27767328
Am J Respir Crit Care Med. 2016 Mar 15;193(6):607-13
pubmed: 26745765
Am J Respir Crit Care Med. 2010 Oct 1;182(7):863-4
pubmed: 20884938
Eur Respir J. 2009 Jul;34(1):95-102
pubmed: 19164344
Am J Respir Crit Care Med. 2019 May 15;199(10):1195-1204
pubmed: 30592902
N Engl J Med. 2018 May 03;378(18):1671-1680
pubmed: 29668352
Eur Heart J. 2019 Dec 21;40(48):3901-3909
pubmed: 31504409
BMJ Open Respir Res. 2019 May 4;6(1):e000431
pubmed: 31258919
J Allergy Clin Immunol. 2016 Jul;138(1):16-27
pubmed: 27373322
Thorax. 2013 Jul;68(7):670-6
pubmed: 22744884
Eur Respir Rev. 2010 Jun;19(116):113-8
pubmed: 20956179
Am J Respir Crit Care Med. 2016 Sep 1;194(5):541-9
pubmed: 27585383
Am J Respir Crit Care Med. 2007 Sep 15;176(6):532-55
pubmed: 17507545
Eur Respir J. 2016 Aug;48(2):320-30
pubmed: 27418551
Acad Emerg Med. 2003 Mar;10(3):198-204
pubmed: 12615582
Circulation. 2000 Oct 3;102(14):1634-8
pubmed: 11015340
Eur Respir J. 2019 May 18;53(5):
pubmed: 30846476
Eur J Heart Fail. 2006 Nov;8(7):706-11
pubmed: 16531114
Respir Res. 2011 Nov 04;12:146
pubmed: 22054035
J Clin Pharmacol. 2012 Mar;52(3):416-24
pubmed: 22090363
J Thorac Dis. 2018 Sep;10(9):5260-5268
pubmed: 30416773
Nephrol Dial Transplant. 2009 May;24(5):1384-7
pubmed: 19208772
Chronic Obstr Pulm Dis. 2015;2(1):23-34
pubmed: 25685850